Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Lance Bredvold who wrote (52007)	1/9/2023 6:41:57 PM
From: Art Bechhoefer	1 Recommendation Recommended By Lance Bredvold Read Replies (1) \| Respond to of 52153

FibroGen made a mess of its application to the FDA for roxadustat and apparently now only looks at the possibility of using roxadustat in the U.S. as an alternative to e-poetin drugs used in chemo treatment. Pamrevlumab still is promising for treating several different fibroses. The company is, in my view, no well managed, but at least its two drugs could eventually cause the share price to move up even more. Art